Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial

Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens
doi: https://doi.org/10.1101/2022.03.25.22272599

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Back to top
Posted March 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens
medRxiv 2022.03.25.22272599; doi: https://doi.org/10.1101/2022.03.25.22272599
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area